The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
May 16 (Reuters) - (This May 16 story has been officially corrected by Amgen to change the pricing estimate in paragraph 4) The U.S. Food and Drug Administration on Thursday granted accelerated ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen’s tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
Amgen Inc. won US approval for a new drug to treat a particularly aggressive form of advanced lung cancer, providing a badly ...
Giovedì la Food and Drug Administration (FDA) degli Stati Uniti ha concesso l'approvazione accelerata al nuovo farmaco della società farmaceutica Amgen (AMGN), tarlatamab, venduto con il nome ...
FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat ...
FRIDAY, May, 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly ...
Avviso esplicito sui rischi: Il trading degli strumenti finanziari e/o di criptovalute comporta alti rischi, compreso quello di perdere in parte, o totalmente, l’importo dell’investimento, e potrebbe ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. The U.S. Food and Drug Administration on Thursday approved a new ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...